Aug. 23 at 7:47 PM
$TGTX I appreciate seeing familiar, long-time posters united in their opinions that a
$73-
$76 buyout offer would be inadequate at this time. If Sub-Q Briumvi is approved for quarterly injections, it's value proposition will be established with payors. Our sales team knows the product and the prescribers. Ocrevus will go off-patent in 2029 and Roche needs to replace that revenue in the MS segment of its business. I believe that we're holding shares in a company that has a strong chance of attaining a
$130-
$160 pps in 1-3 years. That said, if a company with the marketing muscle of
$JNJ were to show up tomorrow with
$120 in cash and shares, I'd take it.
